Esketamine for depression: all studies (page 17)

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Expert Opinion on Therapeutic Targets January 28, 2026 Gia Han Le, Roger S McIntyre 1 citation

Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...

DOI: 10.1080/14728222.2026.2619757 Full text Treatment-resistant depression Esketamine Nmda receptor subunits Antidepressant mechanisms +2

Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.

Journal of Affective Disorders January 28, 2026 Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al. 3 citations

Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...

DOI: 10.1016/j.jad.2026.121257 Full text Esketamine Treatment-resistant depression Intranasal Meta-analysis +2

Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.

BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations

Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...

DOI: 10.1192/bjo.2025.10950 Full text Treatment-resistant depression Esketamine Long-term effectiveness Maintenance therapy +1

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.

Journal of Neuroinflammation January 22, 2026 Ang Liu, Xiao-Qi Zhang, Jia-Xin Guo et al.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and depression frequently co-occur, yet the biological basis of this comorbidity and effective therapeutic strategies remain poorly defined. METHODS: We established a rat model of COPD-depression comorbidity through sequential cigarette-smoke exposure and chronic unpredictable mild stress. Pulmonary function, depression-like behaviors,...

DOI: 10.1186/s12974-026-03699-1 Full text Depression Esketamine Animals Rats, sprague-dawley +8

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

DOI: 10.1186/s12991-025-00626-1 Full text Esketamine Treatment-resistant depression Antidepressant therapies Gcc mental health +2

Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.

Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation

Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...

DOI: 10.1016/j.jad.2026.121208 Full text Esketamine Mdd Treatment-resistant depression Intranasal racemic ketamine +1

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine

BMC Psychiatry January 4, 2026 Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson et al. 2 citations

Abstract Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation...

DOI: 10.1186/s12888-025-07485-w Full text Treatment-resistant depression Major depressive disorder Esketamine Antidepressants +1

Perioperative Ketamine and Esketamine for Postoperative Mood Symptoms After Orthopaedic Surgery: A Systematic Review of Randomized Controlled Trials.

The archives of bone and joint surgery 2026 Ali Dabbagh, Firoozeh Madadi, Maryam Fallah et al.

Perioperative anxiety and depression are common following major orthopaedic surgery and may adversely affect postoperative recovery. Ketamine and esketamine have rapid psychotropic effects; however, their effectiveness in reducing postoperative mood symptoms in orthopaedic patients remains uncertain. We systematically reviewed randomized evidence on the effects of these agents on postoperative...

DOI: 10.22038/abjs.2026.94686.4270 Full text Anxiety Depression Ketamine Orthopaedic +1

Oral Esketamine Maintenance Treatment for Treatment-Resistant Depression: Clinical Outcomes During an Off-Label Treatment Program.

Depression and Anxiety 2026 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker et al.

Ketamine and esketamine maintenance treatment show promise in maintaining initial antidepressant effects, yet further research is needed to optimize long-term outcomes. This observational study aimed to assess long-term depression symptom severity, safety, and tolerability in a cohort of patients receiving at-home oral esketamine maintenance treatment. Between June 2017 and March 2024, 221...

DOI: 10.1155/da/8320239 Full text

Clinician-patient communication in esketamine and psychedelic-assisted treatments for depression: a scoping review of evidence, gaps, and clinical implications

2026 Vassilis Martiadis, Fabiola Raffone, Domenico de Berardis preprint

BACKGROUND: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and represents a critical clinical challenge. Esketamine (S-ketamine, Spravato), approved by FDA and EMA since 2019, and psychedelic-assisted therapies (psilocybin, MDMA) share a pharmacological feature unique among approved psychiatric treatments: they induce altered...

DOI: 10.17605/osf.io/kw4tv

Research